Established in 2006, the McBain Medal is an annual award to honour an early career researcher or technologist who has made a meritorious contribution to colloid and interface science.

The award is intended to recognise both achievement and evidence of future promise. Eligible candidates should be in the UK in the earlier stages of their career, typically within 15 years of attaining their doctorate (or equivalent degree), and will have advanced the science or technology of the field in a significant way. It is named after James William McBain.

On Friday 30 January over fifty people gathered at the Edgbaston Park Hotel at University of Birmingham to celebrate Associate Professor Gemma-Louise Davies winning the annual McBain medal for outstanding early career research in colloid chemistry.

Gemma assembled a fantastic programme of six talks from her collaborators. The day opened with a presentation by Prof Rachel O’Reilly PVC for Research at the University of Birmingham on precision polymer nanoparticles.  Rachel knew Gemma since her time at the University of Warwick, where she acted as Gemma’s mentor. Rachel was also a previous recipient of the McBain medal in 2014. This was followed by a talk by Prof Gareth Williams  from UCL on developing “ Phormulations “ for phages. Gareth and Gemma have being working together since 2017. The final talk before lunch was by Prof Seb Perrier from the University of Warwick on the precision polymer chemistry to design therapeutic materials. Seb is another collaborator of Gemma’s, although they were colleagues at Warwick it was not until Gemma moved to UCL that  they started to collaborate together.

After lunch and posters there were three more talks. Firstly, Prof Nguyen Thanh from UCL presented her group’s work on Nanoparticles for diagnosis and treatment of diseases. Thanh works in a very closely related area to Gemma and they were colleagues at UCL for several years, where she is currently Vice Dean for Innovation and Enterprise. Thanh was also the 2023 recipient of the Thomas Graham prize to recognise her outstanding mid career research in colloids and interfaces. Next to speak was Prof Matt Gibson, again another previous McBain medal winner (2021) from the University of Manchester who spoke about Biomaterials to mimic or target glycans for therapy and sensing. Then, finally Dr Marco Giardiello from the University of Liverpool spoke enthusiastically on tracer design for magnetic particle imaging.  After a quick coffee break and a final chance to look at the posters Gemma closed the event with her McBain medal lecture on Designing MRI based therapeutic and diagnostic tools : From cancer to chemical weapons.

Dr Richard Greenwood and Dr Shirin Alexander present the McBain Medal to Dr Gemma-Louise Davies

The meeting closed with the two Chairs of the Joint Colloids Committee: Dr Richard Greenwood and Dr Shirin Alexander, formally presenting Gemma with the medal and arranging for a photo of her to be taken with the other McBain medal winners present, Rachel and Matt.  Two poster prizes supported be RSC's Journal of Materials Chemistry B and Materials Advances were awarded to Alexandra Billina from University of Birmingham and Christina Puijk from UCL. The organisers would like to thank the sponsors Unilever, RSC's Journal of Materials Chemistry B, CellPress and University of Birmingham and the exhibitor (Asynt) for their kind support of the event.

Six teams have made it to the exciting final of this year’s Bright SCIdea Challenge.

The Bright SCIdea Challenge sees university students develop an innovative science-based idea into a business plan - and then to compete for a £5,000 prize.

SCI supports entrants during the competition by delivering free, exclusive training, and the teams with the strongest business plan are invited to deliver their pitch to an expert panel of experienced, successful senior business people and innovators.

The first Bright SCIdea challenge took place in March 2018 and since then the competition has seen winners go on to launch companies, raise significant funding and take their products to market.

This year’s final - the seventh instalment of SCI’s annual entrepreneurship competition - takes place at SCI’s headquarters on March 17.

Here are the 2026 Bright SCIdea Challenge finalists:

Ascenx

Sophie Siu, William Wang, Justin Wong and Gwen Rico

Where are they from?
University College London

Why did they enter the Bright SCIdea Challenge 2026?
“As second year chemistry students we were keen to apply our theoretical knowledge to a viable business idea under the guidance of industry experts in a fun and dynamic setting. Our entry was catalysed by reading a paper by Kaifeng Wang and Case M. van Genuchten which discussed a novel process of retrieving arsenic from wastewater sludge. We were fascinated by the chemistry and its dual potential of ensuring clean drinking water whilst supplying a sustainable arsenic source. The opportunity to contribute to a meaningful global impact strongly aligned with our humanitarian values and motivated us to participate.”

AvennaX

Josh Das, Peilin Chen and Tara Hudson-Ballard

Where are they from?
Imperial College London

Why did they enter the Bright SCIdea Challenge 2026?
“We entered the BrightSCIdea challenge to accelerate the commercial scaling of AlphaSuite, build a network of other scientific innovators, and gain mentorship from experts. This competiton offers the opportunity to develop our roadmap for market entry, ensuring our innovation is positioned for long term growth. Winning would provide the foundational funding for us to scale our technical infrastructure and secure our IP, and the insights gained from this experience will help us turn our innovation into a successful venture truly valuable to the global research and healthcare community.”

CheGo

Cheyenne Gracias, Chayanit Panjak, Hita Dunukunala and Yunseo Lee

Where are they from?
Kings College London

Why did they enter the Bright SCIdea Challenge 2026?
“Having previously won a hackathon, our team believes real impact comes from bringing solutions to industry which is why BrightSCIdea felt like the right next step. Our inspiration came from a teammate's mother, an experienced ICU nurse, who described how suctioning can cause bleeding and stress for patients and nurses. This sparked our add-on sensor system that transforms standard closed suction catheters into precision-guided medical devices, reducing complications in intensive care. Beyond technical skills, we recognised the need for commercialisation expertise. This competition offers industry feedback, workshops, and funding to develop our prototype into a real product.”

MediKeto

Nano Kojima, Yuri Fujikura and Eleina Hames

Where are they from?
Institute of Science Tokyo

Why did they enter the Bright SCIdea Challenge 2026?
“The ketogenic diet is a highly evidence-based treatment for drug-resistant epilepsy, yet it remains underutilised because of the daily management burden. We built MediKeto to change that.

"As an early-stage team bridging medicine and engineering, the Bright SCIdea Challenge offers something distinct: international validation, critical feedback and support from industry experts, and funding that would directly accelerate our pathway from healthcare app to SaMD. We are determined to refine our concept and empower patients and families who need it most, ultimately boosting treatment adherence and unlocking a better quality of life.”

Napré

Nwachukwu Christiana Okonkwo, Kosisochukwu Judith Offojebe, Ikwuezuma Elochukwu Reynolds and Ekeomodi Chikodi Christabel

Where are they from?
Newcastle University, McGill University, Nnamdi Azikiwe University and Stellenbosch University

Why did they enter the Bright SCIdea Challenge 2026?
“Our participation in Bright SCIdea challenge was driven by our identification of a critical gap in the manufacturing industry: while billions are spent producing drug and food products, the adverse effects of the preservatives used in these products have been largely neglected. We saw an opportunity to change the status quo and create a paradigm shift to safer preservatives while protecting the environment - through the valorisation of agricultural waste. Bright SCIdea offers us an opportunity to connect with visionary partners who share our goal: to disrupt a dysfunctional market with innovative solutions that promote well-being without sacrificing commercial value.”

QROOT — Quantum Reactive Optical Observation of Terrain

Gergo Meszaros, Hassan Raza Khan and Kaden Ethan Tan

Where are they from?
University of Toronto and Brown University

Why did they enter the Bright SCIdea Challenge 2026?
“Uncertainty. Corporations cannot always predict crop yields or the best interventions. Farmers cannot know whether fields will suffer from disease or deplete prior to the first harvest—yet they plant, nurture, and persevere anyway. If they can act despite uncertainty, why shouldn't we? The practicality of scaling a business, of turning innovation into impact, and reaching those who need it most was unknown to us—but because they try, we must too. With BrightSCIdea we have our expertise, the guidance of industry experts, and the network to bring QROOT to life, that is why we are here.”

As an organisation that is proud of its members, SCI is always looking for ways to better serve its community of innovators. That’s why our Director of Stakeholder Engagement, Kirstie Cochrane, and Senior Stakeholder Engagement Manager, Bryony Parker, stepped away from their desks for the day and attended the Memberwise Annual Conference, Membership Excellence.

Membership Excellence is the largest membership focused national conference for the association and membership sector in the UK, which is focused on planning for the future and driving membership growth. As the largest membership-focused event in the country, it is a one-day experience for membership professionals seeking to learn, innovate and excel in membership strategy, engagement, growth and retention.

It's an interesting environment for the stakeholder engagement team to experience as we can learn from other organisations that offer membership to individuals and institutions. The conference was held in London and had over 600 delegates all with a passion for delivering excellence in membership. There were some great Keynote sessions from organisations as varied as the Institution of Engineering and Technology (IET), Institution of Chemical Engineers (IChemE), Royal Horticultural Society (RHS), Parkinsons UK and the National Trust.

What the experts shared

Among a variety of talks was ‘Mentoring in Practice: For both Personal Growth and Member Value’. SCI’s Mentoring Programme has been running for several years, and while this is a popular benefit for both mentees and mentors, this session was really helpful in identifying ways to grow interest and participation from mentors, particularly encouraging women and those from minority backgrounds to take part.

With a fantastic breadth and depth of organisations in attendance it was insightful to hear from the IET about their membership journey, and how they have recently developed a centre of excellence approach which aims to put member engagement as the priority across the entire organisation. This has seen the IET take a member-first approach to sales, customer service, transparency on pricing and process improvements.  

Another highlight was hearing from the RHS about their rebranding and broadening its membership appeal, and how they have used digital innovation and data insight to enhance personalisation, improve member experience, and drive engagement. This has given us a lot to think about from the membership team, on how we provide our membership services and the tools and toolkit that we can use to support our wonderful members. 

So far in 2025, SCI has welcomed more than 830 new members to its vibrant community of scientists, innovators, students and professionals. They contribute to our exceptional programme of events, support the running of our technical and regional groups, showcase how science meets business and recognise each other for scientific awards - it really is one of the most inclusive and supportive organisations.

We are a small team here at SCI supporting membership and we are always looking for ways to facilitate members on their journey through from studying at university, to their first role in a science-based business and beyond with a flourishing career.  We offer support for students to engage with potential employers, cross industry mentoring programme, access to technical content for scientists and a corporate partner network that embodies where science meets business.

Get in touch to find out more about being an SCI member!

Following her insightful SCItalk on Diversity, Equality and Inclusion, Ijeoma Uchegbu, Chair in Pharmaceutical Nanoscience at UCL's School of Pharmacy speaks with Darcy Phillips.

Tell us about your career path to date.

I trained as a pharmacist and then did a PhD at the School of Pharmacy on drug delivery using nanosystems. After about two years of postdoctoral scientist work, I was appointed to a lectureship at the University of Strathclyde in Glasgow. After five and a half years, I was appointed to a professorship in 2002. I then joined the School of Pharmacy as a Professor of Pharmaceutical Nanoscience in 2006 and UCL in 2012.

My work has focused on understanding how drug transport may be controlled in vivo using nanoscience approaches. I co-founded Nanomerics Ltd. with my long-term collaborator – Professor Andreas G. Schätzlein – and next year will see Nanomerics take the technologies developed in academia into clinical testing. This is a huge milestone for our small company and for us personally. I liken this milestone to sending your only child off into the big wide world, and so we are understandably nervous and excited in equal measure!

Science was a refuge for me as I moved countries as a teenager – from London, the city of my birth, to a small town in Nigeria called Owerri. Science subjects were the only subjects that were common on the secondary school curricula of both countries. I really had no other option. I fell in love with science because it was familiar.

Which aspects of your work motivate you the most?

The joy of discovery really gives one a high and this is what I enjoy the most. Validation of one’s discoveries by other members of the scientific community cements the high and when one’s ideas are evidenced first by experimentation and then appreciated by one’s peers, there is no other feeling in the world quite like it.

What has been your proudest achievement?

Getting my professorship so soon after my appointment to a lectureship at the University of Strathclyde is up there with the greatest moments of my career, as is bringing up my daughters at the same time. Oh dear – there are far too many moments to mention, to be honest! Every day I don’t get a rejected paper or grant is really a proud day. Rejections are 90% of a scientist’s life.

You spoke recently at our SCItalk on diversity, equality and inclusion and the importance of data. Could you give us a summary on why this is so important?

To produce good quality science outputs with the maximum impact we need a variety of individuals asking and answering the most profound of research questions. We need more data on diseases and conditions that affect women and more data on the genomics affecting the global southern majority. We need answers to the pressing questions on health outcomes in the poorest in our UK society. Well, you get the picture. We need high quality data on these largely forgotten issues.

What do you think are the next key steps to making STEM more diverse and inclusive?

We first need to recognise that a problem exists. This is the first step. The data on underrepresentation needs to be at the forefront of our thinking when we are making decisions. We need funders to acknowledge the deficit in the current ways of doing things and then commit to act appropriately. The oddest thing about a skewed and unequal system is that we all lose out when there are entrenched inequalities. Even those that think that they are gaining from the current system are not.

We catch up with Zoë Henley, a Medicinal Chemistry Lead at GSK and recent recipient of a Rising Star Award in the category of Science & Engineering

Tell us about your career path to date.

Growing up, I loved science and have early memories of playing with my beloved chemistry set. However, it wasn’t until my A-levels that I knew I wanted to study chemistry at university. I had an inspiring chemistry teacher who supported me to apply, and I ultimately gained a first-class MSci chemistry degree from the University of Bristol.

I joined GSK as an Associate Scientist in 2006 and in my early career I was focused on identifying new molecules to treat respiratory diseases. As a chemist, I use my synthetic and medicinal chemistry skills to identify potential drug candidates, one of which reached Phase 2 clinical trials in patients for the treatment of Chronic Obstructive Pulmonary Disease, which is a life-threatening lung condition with no current cure. I have also led discovery efforts on early-phase research projects to validate the exact role a potential therapeutic target plays in a disease, which is critical for initiating a drug discovery programme.

Through my work, I developed deep technical skills in inhaled drug design and was appointed chair of a technical network for inhaled drug discovery programmes within GSK.

Alongside my work in the laboratory, I also developed my technology skills to become the lead user in Europe for drug compound design and data analysis software.

I was promoted to a Scientific Investigator in 2013 and achieved my PhD in 2014, through a collaborative programme between GSK and the University of Strathclyde. In September 2021, I was promoted to Team Leader.

Over the period I have been a team leader, I have supported 12 scientists and have had the opportunity to mentor graduate chemists and supervise one-year industrial placement students. I am currently a project Medicinal Chemistry Lead and have three direct reports who I support in their professional and scientific development at GSK.

‘I am passionate about science and the job that I do, and am committed to being an advocate for female leaders in chemistry.’ Image: Zoë Henley

Which aspects of your work motivate you the most?

I find the job of a medicinal chemist fascinating and highly rewarding. As a chemist, I have the opportunity to make the molecule that becomes a medicine to help patients, and this is my greatest motivation. Medicinal chemistry is a fast-paced, constantly evolving field that requires diverse skill sets. I find it refreshing to work within a diverse team, in particular working internationally across our global organisation, where I have had experience of working with colleagues across scientific disciplines and from different cultures and backgrounds who bring varied perspectives.

You were recently recognised with a Rising Star Award in the category of Science & Engineering, do you have any advice for anyone starting out their career in this field?

I am passionate about science and the job that I do, and am committed to being an advocate for female leaders in chemistry. For those starting out in this field, I would encourage them to follow their hearts and make well-informed career and personal choices to fulfil their dreams. Whenever I have had decisions to make, I have relied on close friends and mentors for advice, and I would encourage others to identify role models and seek their mentorship. I would also advise pursuing anything you feel passionate about. This might mean, for example, developing a new skill or gaining deeper expertise.

‘GSK as an organisation is highly supportive of flexible working, and within my own department I have continually had support for my professional development, in particular when I returned to work after one year maternity leave.’ Image: Zoë Henley

You’ve been working at GSK for a number of years now – can you tell us a bit more about how they’ve supported you in your career and allowed you to balance this with family life?

Throughout my career at GSK I have had so many opportunities to develop professionally and personally. Alongside continuously developing my technical skills, I have been able to carry out a PhD whilst still a full-time employee of GSK, participated in STEM outreach activities, had supervisory responsibility for both GSK employees and PhD students on collaborative projects, and I have been asked to take leadership roles in many different settings.

In 2019, I became mum to my son Sam, and I have since progressed my career whilst working part-time. I had very few female role models until I came to GSK, where the number of female chemists is high and there were many who had families and successful careers, which gave me confidence that I could have the same.

GSK as an organisation is highly supportive of flexible working, and within my own department I have continually had support for my professional development, in particular when I returned to work after one year maternity leave. My manager was highly supportive of my continued trajectory towards taking a leadership role and supported me in applying for a Deep Dive Career Programme at GSK, which is a competitive programme for future leaders who want to actively shape their career journey.

The programme allowed me to set out a detailed personal development plan and helped to expand my network. The leaders of my department also offered me managerial responsibilities, and this ultimately empowered me to apply for and achieve a Team Leader position.

I have a successful career/family life and aim to give other chemists the confidence that they can achieve the same.

If you'd like to hear more from inspiring female scientists like Zoë take a look at our upcoming SCItalk on Wednesday 27 September: Women in STEM: Better Science and a Better Workplace for Everyone.

Accelerating the transition to a sustainable global energy system

Welcome to the first in this series from the SCI Energy Group – we’ll be blogging regularly on topics of broad interest across the energy spectrum.

Andy Walker, Chair of the SCI Energy Group.

I’m Andy Walker, and I have the privilege of chairing the Energy Group, which comprises members drawn from industry, research institutes, universities, energy policy bodies, R&D organisations and scientific publishers. We meet regularly to discuss and organise events around the changing energy landscape, exploring challenges and opportunities associated with the clean energy transition.

We inform and influence climate change dialogue and policy in the UK and further afield, by taking a fact-based approach to the challenges and potential solutions, with the ultimate aim of making the global energy system sustainable. We do this by bringing together experts, influencers and other interested parties from across the technology, social science and policy landscape within industry, academia and government. In this way, the SCI Energy Group offers thought leadership, insight and debate around the clean energy transition.

Recently, the Energy Group Committee visited Imperial College London and were given a fascinating tour of the carbon capture and storage pilot plant, which Committee member Alex Bowles had very kindly organised. This was a really interesting visit, hosted by Dr Colin Hale and several enthusiastic and knowledgeable chemical engineering students, focused on the critical role that the capture and long-term storage (and utilisation) of CO₂ will play within the clean energy transition. We learned that carbon capture utilisation and storage (CCUS) can play four critical roles in the transition to net zero:

1. Tackling emissions from existing energy assets, for example by retrofitting existing fossil fuel-based power and industrial plants, by capturing the CO₂ emissions emitted during these processes.
2. As a solution for sectors where emissions are hard to abate, such as the in-process emissions during cement manufacture (one of the largest industrial sources of CO₂ today).
3. As a platform for clean hydrogen production – almost all of the 90 million tonnes of hydrogen generated today is via methane steam reforming, which emits around 10 tonnes of CO₂ for every tonne of hydrogen produced.
4. Removing CO₂ from the atmosphere to balance emissions that cannot be directly abated or avoided (so-called direct air capture, DAC).

The International Energy Agency (IEA) estimates that the amount of CO₂ captured and stored annually in their Sustainable Development Scenario rises to around 9.5 Gt per year by 2070, with another 0.9 Gt CO₂ captured and used to make, for example, fuels and chemicals. (Note that a Gigatonne (Gt) is one billion metric tonnes).

IEA, Growth in world CO₂ capture by source and period in the Sustainable Development Scenario, 2020-2070, IEA, Paris. Licence: CC BY 4.0

The Energy Group plans to visit several other sites of interest in the coming months, including Drax and the Energy Innovation Centre in Birmingham, so look out for updates from these future visits.

Our next blog will relate to a recent workshop on Energy Storage, which we organised with strong support from Innovate UK/Knowledge Transfer Network. We brought in representatives from industry, academia, government and the finance sector to discuss this broad topic and to identify the key challenges, as well as outline some key policy questions for the government.

We chose this topic because energy storage is a critical part of the clean energy transition, as the world moves towards an increasing dependency on renewable sources of energy, which are inherently intermittent, yet it doesn’t receive enough attention and support from governments around the world. We’re sure you’ll find the outputs from this workshop very interesting!

CCU International will supply its carbon capture and refinement system to Flue2Chem – a project led by SCI and Unilever which aims to convert industrial waste gases to create more sustainable consumer products. We caught up with CCU International CEO, Beena Sharma, to talk about her career path, motivations and challenges.

Tell us about your career path to date

I joined the Oil & Gas industry after university and began my career as a behavioural safety specialist, specifically for the construction phase of oil and gas projects. Soon after I joined the industry, I was assigned to an LNG plant in Nigeria for training and experience and eventually ended up at a gas plant in Norway before I returned to the UK. With both a psychology and training background I found myself working within a health, safety and environmental remit for various industries including healthcare, construction, manufacturing, and even the tobacco industry.

Beena and colleague at a gas plant in Norway, 2004. Image credit: Beena Sharma

What made you want to work in science and the environmental technology sector in particular?

When I moved to Scotland six years ago it gave me the opportunity to explore the ‘E’ in Health, Safety and Environment further, which was an area that I was always interested in but rarely got the attention it deserved in the industries I worked in. I volunteered on a Scottish climate change project, and this led me to think more deeply about the scientific and technological advances that were needed to achieve net zero by 2045 in Scotland. I knew this was a huge challenge with education, and changes in habit alone could not solve it.

I began to research solutions for hard-to-abate industries and areas that were a challenge to decarbonise, and set up my first business focused on a novel approach to insulating legacy buildings. I then worked on setting up a group of companies that included a solar PV installation company as well as a cleantech business that utilised an electrolysis technology to ozonate tap water for disinfection.

I was invited by my now business partner to help launch a biotechnical business that could create a circular food economy, taking food waste and creating microalgae for use in industries such as cosmetics, pharmaceuticals, and animal feed. This business incorporated 4 technologies, one of which was carbon capture. After some discussion with potential investors, it became clear that there was a huge interest and demand for carbon capture solutions. This led the team to decide to spin out CCU International as a separate entity and speed up the commercialisation of the technology which had been in development at the University of Sheffield under the lead of Peter Styring, Professor of Chemical Engineering and Chemistry.

Which aspects of your work motivate you the most?

The aspects of what I do that motivates me the most is the educational role that I play as the CEO of the business. I am regularly invited to speak on panels, podcasts, webinars and at conferences to share my knowledge with an industry that is transitioning and eager to learn, grow and incorporate new ways of thinking and doing things. It is extremely rewarding to see that people have come away from listening to me with a new perspective and being inspired to go away, take that learning, incorporate it in their ways of working and become innovators themselves.

According to the UN, carbon capture will be a key technology in achieving net zero. It is extremely rewarding to know that the CCU International technology will be a major contributor to this goal and that we can enable decarbonisation with the technology usage across multiple industries, both large and small, which otherwise would not have been possible.

What have been the biggest challenges for you as an entrepreneur?

As an entrepreneur my biggest challenge has been establishing myself in an industry and environment that is not well represented by women, and in particular women of colour. Often, it comes as a surprise to many that I would be heading up such a business and unfortunately many biases still exist within all genders and backgrounds. It makes it that extra bit harder and there can be a requirement to prove oneself as credible through knowledge or capability before the respect is given.

Image credit: Beena Sharma

The other big challenge has been around the education we provide for all our stakeholders. Innovation is not always welcome, especially in an industry or area where it may seem innovation is not needed. As the saying goes, ‘if it’s not broke, don’t fix it’, so stakeholders tend not to realise there is a problem until we educate them on the solution! And not many can accept there may be a better way of doing things than what they themselves have been doing for years!

What would be your top piece of advice for anyone thinking of starting up their own SME?

Starting up in business is a step that many think about doing but very few actually do. Most would be led to believe that you would need to work for months, maybe years on market research, business planning, strategy etc. before starting a business. My one piece of advice would be to start. Most of what you learn will come from doing. It is essential for entrepreneurs to fail, make the mistakes and learn what not to do next time so you have a better chance of success going forward. Many successful businesses emerge from failure.

What is it about the Flue2Chem project that is unique, what made you want to get involved, and what is the potential difference this project could make?

The Flue2Chem project is aimed at converting industrial waste gases into sustainable materials for use in consumer products. What is unique about the Flue2Chem project is that organisations that would normally be competitors have come together to find a solution for a problem that affects us all – as people, as businesses and as a planet. It is rare to see such cross-industry collaboration on this level and this allows both cross-learning and inspires others to come together, collaborate and innovate to solve problems that affect us all, much like the Flue2Chem project. It is a privilege to be part of the project by contributing our technology to the capture component.

CCU International, carbon capture technology. Image credit: Beena Sharma

The project will play a key role in supporting the UK’s 2050 net zero ambitions by providing a more sustainable feedstock for products such as household cleaning materials. The project could demonstrate how the UK could cut 15-20 million tonnes of carbon dioxide emission each year. The UK imports large quantities of carbon containing feedstocks that we use in the consumer goods industry. The project will demonstrate how we can secure an alternative domestic source of carbon for these goods and also demonstrate how industry can contribute towards achieving net zero.

Why do you think collaboration of this scale is so important?

Industry coming together to solve climate change issues is essential if we are ever to achieve net zero. Collaboration of this scale sends a strong message and emphasises that change in approach is needed and that innovation is key. This inspires others to do the same. Solutions are needed now and by bringing expertise and experience together we learn and adapt quicker. Solutions are needed now – not in years to come.

The impact this project will have has the potential to be huge, across multiple industries and certainly with how we look at not only capturing carbon emissions but also what we can do with the captured carbon dioxide, promoting a circular carbon economy where in time we learn to value carbon dioxide in a way that has never been done before.

Certainly, for the carbon capture storage community, this project will show that there is a use for captured carbon dioxide other than treating it as a waste and sequestering in underground oil reservoirs. Utilising captured carbon dioxide can create revenue streams for any business or process that emits carbon dioxide.

The collaboration demonstrates the commitment from industries to support decarbonisation, of those industries that are hard to abate whilst at the same time building a new UK value chain.

Are you interested in pharmaceutical R&D? Which PhD skills are particularly useful in industry? We asked James Douglas, Director of Global High-Throughput Experimentation at AstraZeneca.

Tell us about your career path to date.

I currently have two roles, firstly as Director of Global High-Throughput Experimentation (HTE) within R&D at the pharmaceutical company AstraZeneca. I also work one day a week as a Royal Society Entrepreneur in Residence at the Department of Chemistry in the University of Manchester. Both roles involve developing and applying methods and technology in chemical synthesis to facilitate the drug discovery, development, and manufacturing processes.

My journey to these roles began with a chemistry degree and a passion for running chemistry experiments in the laboratory. At the end of my undergraduate MChem degree at the University of York, I spent an amazing placement year at the pharmaceutical company GlaxoSmithKline, working in drug development. I then went on to do a PhD at the University of St Andrews and postdoctoral research in the USA, both of which focused on developing new methods for synthesis.

My PhD was in collaboration with AstraZeneca and my postdoc was with the pharmaceutical company Eli Lilly, so I knew a lot about medicines R&D and wanted to start a permanent career in that industry.

Pictured above: James Douglas

When did you start working for AstraZeneca?

I started at AstraZeneca in 2015. Initially, I spent most of my time working in the laboratory, supporting drug projects across a range of therapy areas such as oncology, heart disease and respiratory treatment. Since then, I have gradually spent less time in the lab across multiple roles and more time working with – and leading wider teams – with a more company-wide focus.

I have remained closely linked to academic research and universities through collaborative projects. This ultimately led me to the Entrepreneur in Residence role where I am accelerating the translation of chemistry innovation from academia to industry, as well as helping provide students and researchers skills and networks relevant to careers in industry.

What is a typical day like in your job?

I spend about two days a week on site at AstraZeneca in Macclesfield and two working from home. As my main job is office based I can also work from home very easily. It has been this way for me since the start of the pandemic. I missed the general atmosphere of a busy workplace but this period coincided with the birth of my daughter, so I feel lucky to have been able to see a lot more of her growing up than I would have otherwise.

I work with many scientists across the company, not just in Macclesfield, such as in Cambridge (UK), Boston, and Gothenburg, so virtual meetings and calls are a big part of my day. When I’m on site, I prioritise face-to face meetings and discussion with the scientists in the laboratory. Very occasionally I get the chance to run some experiments myself, which I really enjoy.

Since 2022, I have spent Fridays within the Department of Chemistry at the University of Manchester. I talk to academics and PhD students about how their research could be applied in industry, discuss current projects, and think up new ones. I’m also preparing a lecture course and organising careers and networking events to prepare students with skills that are important for careers in industry.

Which aspects of your job do you enjoy the most?

I still get the most excited when faced with the challenge of solving difficult scientific problems. This has changed during my career from working individually in the lab, on relatively clear problems during my PhD, to now being part of much larger teams trying to solve highly complex longer term challenges.

Chemistry is always advancing but so are the standards that we must push towards in drug development – for example, finding ways to shorten the time taken to bring new treatments to patients, while at the same time significantly reducing the environmental impact. That’s a daunting – but exciting – opportunity for synthetic chemists like me.

Most of all, even though the timelines are longer on the projects I work on now, there are moments of short-term success that are exciting. This could be an experimental result from the team that opens up a new possibility, or provides important insight into how best to proceed.

>> Side projects can make large waves. Dr Claire McMullin shares the insights from her journey.

What is the most challenging part of your job?

I miss being able to dedicate my time to experimental work and really understanding a problem in detail. I have spent much of my career investing the large amount of time it takes to understand a problem and think about solutions. Unfortunately, that’s no longer the case and not my main responsibility, but I still find this hard to accept!

I miss the level of detail and discussion I once had and find it a challenge not to spend all my time in the laboratory bothering all the brilliant scientists with questions about what they are doing.

How do you use the skills you obtained during your degree in your job?

Most directly, my degree gave me great general skills in chemistry, ranging from practical experimental techniques to chemical analysis and fundamental principles such as kinetics. These were the basis on which I built more specialised skills in organic synthesis during my PhD and postdoc, all of which are crucial for my career so far.

There are also lots of skills I developed that I didn’t appreciate at the time, such as time management, the ability to think independently, organisation, and teamwork. Like many others, my PhD and postdoc also taught me important lessons about resilience and perseverance.

What advice would you give others interested in pursuing a similar career path?

It’s not advice, but what worked for me was to do what I am passionate about. Don’t worry if it takes a while to work out what that exactly is. I decided to do a chemistry degree mostly because I thought I would enjoy the practical experimental side, which I did and still do. It was only during my final year placement at the pharmaceutical company GSK that I decided to do a PhD so I could learn new areas of chemistry.

Finally, it was only during my postdoc that I decided to try and solve the challenges faced with drug development in industry, rather than the more fundamental undertaken as a research group leader in academia.

I’m still finding out what things interest me and these interests keep changing. That’s the joy of disciplines like chemistry and drug development – there is always so much more to learn and challenges to overcome.

How do you forge a career in process chemistry, and how do you overcome the challenges of studying in your second language? Here’s how Piera Trinchera, Associate Principal Scientist at Pharmaron, found her way.

Tell us about your career path to date.

I am an Associate Principal Scientist in the Process Chemistry department of Pharmaron UK. I am based at the Hoddesdon site in Hertfordshire, where I develop synthetic routes for the manufacture of new drugs for clinical studies.

I’m originally from Italy. I completed my MSci at the University of Salento followed by a PhD in organic chemistry at the University of Bari, focusing on new synthetic methodologies. Despite my complete lack of English at the time, I jumped at the opportunity of a six-month visiting PhD position at the University of Toronto.

This was a challenging experience initially as it was my first time living abroad, but ultimately it was very rewarding. After completing my PhD I returned to the University of Toronto to undertake a postdoctoral position focusing on organoboron chemistry. I followed this with a second postdoc at Queen Mary University of London working on aryne chemistry.

After eight years in academia, I wanted to apply the knowledge I had acquired to solving industrial problems that directly impact people’s lives. For this reason, I joined Pharmaron UK where I have been for the last three years and am currently a project lead and people manager.

What is a typical day like in your job?

I am involved in multiple projects each year and the overall aim is to provide synthetic chemistry solutions for our global clients. Depending on the type of project work, this can include either developing brand new synthetic routes to novel drug candidates or troubleshooting and improving existing chemical processes, making them suitable for large-scale manufacture.

Ultimately, the goal across all projects is the same: to support the production of large quantities of drugs that are needed for clinical studies with a line-of-sight to commercial production.

On a typical working day, I spend the majority of my time in the lab where I conduct my own experiments and lead a team of chemists who work alongside me. I am directly involved in the planning and designing of experiments, execution in the lab, and subsequent manufacture on multi-kg scale in our pilot plant.

Over the course of a project, a large part of the job is communicating to the clients the project strategy, scientific results, and timelines through regular teleconferences, emails, and written reports.

>> Read how side projects made large waves for Dr Claire McMullin

Which aspects of your job do you enjoy the most?

There are many aspects of this job that I enjoy. I have always enjoyed solving new scientific problems, with the thrill of impatiently waiting for the results of an important experiment or the curiosity in trying to understand an unexpected result.

In addition to the science, seeing your day-to-day lab work translated to the production of kg-quantities of new pharmaceutical compounds that might, after clinical studies, further global health is very rewarding.

Projects are completed on much shorter time frames than in academia (three to six months) and there is no time to stagnate as one so often does in a PhD or Postdoc. I enjoy the large breadth in the chemistry and the different challenges that come with each and every project.

Last but not least, it takes many people from different departments (e.g. in analysis, quality assurance, or manufacturing) working closely together to manufacture a drug compound on a kg-scale.

Working so closely with people from different backgrounds has tremendously enriched me during these years in Pharmaron. It has allowed me to acquire new technical knowledge and given me a deeper understanding of not just chemistry but the overall requirements for synthesising pharmaceutical compounds.

What is the most challenging part of your job?

Preparation of a synthetic process for manufacture on a kg-scale involves considerable development in the laboratory to ensure the chemistry translates from small to large scale. Part of this development is to identify potential issues and blindspots of the chemistry and processes and mitigate them by improving the process before implementation on a large scale.

Despite all these efforts, unforeseen complications do occasionally occur on the large scale and finding solutions in real time can be the most challenging aspect of the job. By keeping a clear head, the chemist can leverage both their deep knowledge of the process and the experience of their more senior colleagues to solve these problems.

How do you use the skills you obtained during your PhD and postdocs in your job?

As I’m in a synthetic chemistry job, I have benefitted enormously from the theoretical organic chemistry knowledge and practical laboratory skills that I acquired over the course of my PhD and postdoc years.

Additionally, in academia I became familiar and confident with other skills that I use on a daily basis. These include scientific communication through either written reports or oral presentations, conforming to good laboratory safety practices, and supervising and mentoring other people.

>> Get involved in the SCI Young Chemists’ Panel.

Which other skills do you need for your work?

Teamwork is a cornerstone of the job and company’s culture. The synthesis of pharmaceutical compounds according to our quality standards would not be possible without the contribution from, and close collaboration among, multiple people across several departments including analytical chemistry, process chemistry, process safety, quality assurance, formulation and manufacturing.

Is there any advice you would give to others interested in pursuing a similar career path?

Don’t be afraid to venture outside of your comfort zone and be open to opportunities, especially those that don’t come along as often. This will help you build your confidence and you will likely find that you can do more than you anticipated. If you are interested in process chemistry, I would recommend looking into internships and/or finding a mentor who can give you an insight into the job.

As with research, perseverance is an important skill you need to master. You will experience failed reactions and difficult purifications at some point in your career as a process chemist. Be open minded, ask questions and don’t be afraid to seek out support from your colleagues.

>> Read how Ofgem’s Dr Chris Unsworth creates an inclusive working environment and transfers his PhD skills.

In the second part of our chat with Bright SCIdea finalist Team Eolic Wall, we found out how they prepared for their presentation and judges’ questions, and what’s next for their innovative wind turbine technology.

The road from Eureka moment to finished product is paved with peril. Team Eolic Wall’s idea for small, modular wind turbines that use magnetic levitation to harness more power than existing turbines could bring wind power generation into our very homes. But bringing a groundbreaking product to market is not just about mastering the science. It must make business sense too.

As with the other Bright SCIdea hopefuls, Team Eolic Wall received free training from SCI in the form of online tutorials from experienced professionals including modules on structuring a business, financial modelling, branding, and marketing.

After completing the training, Eolic Wall rose to meet the challenge. The team qualified for the Bright SCIdea final and, with it, the pivotal presentation in front of a live audience and panel of expert judges.

Many of us take it as a given that we speak to people at work in our native tongue. The nuances of communication – the cultural subtleties and oddities of the English language – aren’t a concern. But Team Eolic Wall had to present in their second language.

Pitch perfect?

‘This was not our first international presentation, but it was the first one in a foreign language,’ said Alfredo Calle, Eolic Wall founder, ‘so that's always a little bit intimidating until one gets used to it.’

The key to them nailing the pitch was in the spade-work. Calle and his colleagues rehearsed the speech until they knew it by heart. ‘It’s all about training and preparation,’ he said. ‘The more you rehearse, the more confident you feel when the presentation moment comes.’

Of course, the presentation is predictable but the judges’ questions are less so. Having undergone the rigours of competition, Calle recommends that this year’s entrants prepare by trying to predict the types of questions they will be asked. A cold rehearsal could help with the potentially stunning situation of someone throwing questions at you from strange angles.

That team Eolic Wall presented its technology online made theirs even trickier still, especially given a technical hitch at the beginning. But they had polished the presentation to a smoothness that offset such difficulties and came away as joint winners of the Audience Award.

The only lingering regret for them was that Covid prevented them from coming to London. ‘We wish we could have made it to the final,’ he said. ‘Facing the judges and audience live would have been a tremendously valuable and enriching experience.’

A wind energy democracy

Since the Bright SCIdea final, the Eolic Wall is being built brick by brick. The team has received three grants in recent months including one from ProCiencia, the largest innovation agency of the Peruvian government.

Eolic Wall's wall-mounted wind turbine is designed to power homes and offices in situ.

However, perhaps the most exciting development is the technology itself. ‘We have accomplished a peripherally supported wind turbine that works with magnetic levitation,’ Calle said. ‘That's a huge milestone that makes us believe we are building something big.’

Calle hopes for more investment to develop the technology further. At heart, he believes the Eolic Wall will give regular people the chance to generate affordable wind energy from home.

‘We are working out a solution to democratise wind energy for the sake of this blue rock we call home.’

>> Find out how Team Eolic Wall’s innovative technology in part 1 of this blog.

Do you know how the Academy Awards came to be named the Oscars? What about the story behind the Nobel prize? Behind every award name there is a story, and the Julia Levy Award is no exception.

On the face of it, the Julia Levy Award is about innovation in biomedical applications, but it is the stories of the winners of this SCI Canada award, and Julia Levy herself, that really give it life.

But for a tweak of history, Julia Levy may not have ended up in Canada at all. Born Julia Coppens in Singapore in 1934, she moved to Indonesia in her early childhood. Her father uprooted the family during the Second World War and she left for Vancouver with her mother and sister – her father only joining them after release from a Japanese prisoner-of-war camp.

Julia and her family moved to Vancouver during the Second World War.

After studying bacteriology and immunology at the University of British Columbia (UBC), the young Julia received a PhD in experimental pathology from the University of London. She went on to become a professor at UBC and helped found biopharmaceutical company Quadra Logic Technologies in 1984.

More important than confining her achievements in cold prose, Julia Levy’s work made a profound difference to people’s lives. She developed a groundbreaking photodynamic therapy (PDT) that treated age-related macular degeneration – one of the leading causes of blindness in the elderly. She also created a bladder cancer drug called Photofrin in 1993 and, according to Neil and Susan Bressler, the Visudyne PDT treatment created by Julia and her colleagues was the only proven treatment for certain lesions.

Levy thrived in the business space too, serving as Chief Executive Officer and President of QLT from 1995 to 2001. She has since won a boatload of awards for her achievements, but sometimes the best testimonies come from those who have been inspired by her achievements.

Trailblazing drug discovery systems

For Helen Burt, winner of the 2022 Julia Levy Award and retired Angiotech Professor of Drug Delivery at the University of British Columbia (UBC), Julia has been an inspiration. Here was this UBC professor who jointly founded this big, exciting company – creating medication that improved people’s lives and showing her what was possible.

Helen, an English native, moved to Vancouver in 1976 for her PhD and loved it so much that she stayed. As a professor at UBC, Helen would become a trailblazer in drug delivery systems – a field pioneered earlier by Julia Levy.

‘I was a new assistant professor when she was building Quadra Logic and I would go to talks that she gave,’ Helen said. ‘Essentially, the early technology for QLT was a form of very sophisticated drug delivery [...] It was getting the drug they developed into the eye and irradiating it with light of a specific wavelength.

‘It was very, very targeted. And so, you didn’t get the drug going elsewhere in the body and causing unwanted side effects. So her technology was a form of very advanced drug delivery technology.’

‘For me to win an award that honours Julia Levy and her achievements – I think that's what makes it so special to me.’ – Professor Helen Burt, a former student of Julia Levy, is the Award's most recent recipient.

>> Learn more about SCI Canada.

These talks chimed with the young Helen. If a microbiologist could develop this kind of technology, what was stopping her from developing her own?

She, too, became a pioneer in her field, developing nanoparticle-based drug delivery systems (including those to treat cancer) and a novel drug-eluting coronary stent. According to Professor Laurel Schafer, who put Helen forward for the Julia Levy Award: ‘[Helen] was a trailblazer in new approaches for drug delivery and in research leadership on our campus.’

Importance to Canadian chemistry

Professor Schafer is a hugely accomplished chemist in her own right; and the University of British Columbia chemistry professor’s achievements in catalysis discovery were recognised with the LeSueur Memorial Award at the 2020 Canada Awards.

Julia Levy provided an inspiration to Laurel too, in her case as an exemplar for what Canadian chemists could achieve. ‘The achievements of Julia Levy show that it really can be done right here in Canada, and even right here in British Columbia,’ she said. ‘I grew up in a Canada where I believed that better was elsewhere and our job was to attract better here – a very colonial attitude.

Julia studied at and later became a Professor at the University of British Columbia – the campus is pictured above.

‘I now believe and know that better is right here. Professor Levy’s work showed that world-leading contributions come from UBC and from the laboratories led by women.’

She noted that the Julia Levy Award acknowledges Canadian innovation in health science, whereas Canadian chemistry has historically focused on process chemistry in areas such as mining and petrochemicals.

But Julia Levy’s influence permeates beyond science. ‘Julia is one of those people who has been willing throughout her whole career – even now, well into her eighties – to give back to the community,’ Professor Burt says. ‘She mentors, she coaches, she sits on the boards of startup companies, and she advises.’

‘She’s just got this incredible amount of knowledge… She was the Chief Executive Officer [at QLT], so she learnt all of the aspects: the complex and sophisticated regulations, knowing how to find the right people to conduct clinical trials, and how to do the scale-up. She really is a legend in terms of giving back to the community. And this is not just in British Columbia – it’s Pan-Canadian.’

Pictured above: Julia Levy

For young chemists, the Julia Levy in the Julia Levy Award may just be a name for now, but for those in the Canadian chemical industry and patients all over the world, her influence and her work resonate.

As Professor Helen Burt said: ‘For me to win an award that honours Julia Levy and her achievements – I think that's what makes it so special to me.’

>> For more information on the Canada Awards, go to: https://bit.ly/3VMwNKa

Imagine owning a small wind turbine that generates all of your home’s energy needs. As the clock counts down on entries for for the 2023 Bright SCIdea Challenge, we caught up with Team Eolic Wall, the Audience Winner for the 2022 competition.

Eolic Wall was always a nice fit for Bright SCIdea. The team spotted a problem in our renewable energy mix and came up with a scientific business idea to solve it. They saw that wind energy is generated for the public, but it isn’t generated by the public. This stands in bright contrast to solar power generation.

‘Today, 40% of all installed capacity in solar energy is based on solar panels installed on the rooftops of home and corporate buildings,’ said Alfredo Calle, founder of Eolic Wall. ‘The remaining 60% correspond to solar farms.’

Eolic Wall's wall-mounted wind turbine is designed to power homes and offices in situ.

The wind industry is different. ‘Only 1% of the installed capacity comes from households and businesses,’ he added. ‘That is, 99% of all installed capacity in the world comes from wind farms. That sort of concentration is a problem that hampers the energy transition.’

Calle believes this disparity hampers the move from fossil fuel dependency to clean, renewable energy. For many, micro-generation is key. We need to put power – renewable power – in the hands of the people. His idea is to make wind energy available in the home, just as solar exists on roofs everywhere.

The scale of this task is daunting. It turns out there’s a reason why we don’t all have wind turbines bolted onto our homes. The problem, Calle argues, is that a windmill must be large to be efficient.

He believes the Eolic Wall could change that – that this wall-mounted wind turbine is efficient enough to power our homes and offices.

‘We have created a technology that not only doubles wind speed to harvest more power from the same wind resources, but also has a wind turbine that works with magnetic levitation to almost eliminate any friction.’

From applicant to finalist

So, how did a team based out of the National University of Engineering in Peru and Universidade Estadual Paulista in Brazil end up competing for the £5,000 first prize in the Bright SCIdea final?

Chance. Fortune. Happenstance. Calle and his colleagues came upon Bright SCIdea through a social media post that immediately captured their attention.

‘We thought that the Eolic Wall was ideal for Bright SCIdea because of the huge positive impact that this technology could have,’ he said, ‘and also because it perfectly fit into Bright SCIdea’s thesis of supporting ideas in the intersection of business, innovation and science.’

Applying was simple, although the business plan submission was intimidating at first. However, like all BrightSCIdea applicants they received coaching, and their brainchild found form.

‘The key driver to overcome that challenge was not to miss any training sessions and tutorials,’ Calle said. ‘The good news is that after going through the whole process you feel that everything was worthwhile. No pain, no gain.’

Check out fellow 2022 finalist Klara Hatinova from Team Happy BioPatch in conversation with the Periodic Fable podcast.